1
|
Kennedy WR, Chang YW, Jiang J, Molloy J, Pennington-Krygier C, Harmon J, Hong A, Wanebo J, Braun K, Garcia MA, Barani IJ, Yoo W, Tovmasyan A, Tien AC, Li J, Mehta S, Sanai N. A Combined Phase 0/2 "Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma. Int J Radiat Oncol Biol Phys 2023; 117:e115. [PMID: 37784657 DOI: 10.1016/j.ijrobp.2023.06.898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) This study evaluates the pharmacokinetic (PK) and pharmacodynamic (PD) profiles and clinical efficacy of PARP1/2 selective inhibitors, pamiparib and olaparib, in newly-diagnosed or recurrent glioblastoma (GBM) patients in combination with radiotherapy (RT). MATERIALS/METHODS In this combined phase 0/2 trial presumed newly-diagnosed (Arm A) or recurrent (Arm B) GBM patients received 4 days of pamiparib (60 mg BID) prior to resection either 2-4 or 8-12 hours following the final dose. Arm C enrolled patients with recurrent GBM to 4 days of olaparib (200 mg BID) prior to resection. Enhancing and nonenhancing tumor tissue, cerebrospinal fluid (CSF) and plasma were collected. Total and unbound drug concentrations were measured using validated LC-MS/MS methods. A PK 'trigger', defined as unbound drug and gt; 5-fold biochemical IC 50 in nonenhancing tumor, determined eligibility for the therapeutic expansion phase 2. PARP inhibition was assessed via ex vivo radiation and quantification of PAR levels compared to non-radiated control. Newly-diagnosed MGMT unmethylated GBMs and recurrent GBMs exceeding the PK threshold were eligible for an expansion phase of pamiparib (Arms A and B) or olaparib (Arm C) with concurrent RT followed by maintenance pamiparib or olaparib. RT was 60 Gy in 30 fractions in newly-diagnosed patients and 40 Gy in 15 fractions in recurrent patients, delivered using volumetric-modulated arc therapy (VMAT). RESULTS A total of 38 patients (Arm A, n = 16; Arm B, n = 16; Arm C, n = 6) were enrolled in the initial phase 0 study. The mean unbound concentrations of pamiparib in nonenhancing tumor region for Arm A and Arm B were 167.3 nM and 109.4 nM respectively, and in Arm C the mean unbound concentration of olaparib was 5.2 nM. All patients in the pamiparib arms (n = 32/32) but only 1 of 6 patients in the olaparib Arm C exceeded the PK threshold. Radiation-induced PAR expression was 2.44-fold in untreated control vs 1.16 in Arm A (p<0.05), 0.85 in Arm B (p<0.01) and 1.11 in Arm C patients, respectively. In Arm A, 11 patients had unmethylated tumors, and of those, 7 patients enrolled in phase 2. In Arm B, 9 of the 16 clinically eligible patients with positive PK results were enrolled in phase 2. At a median follow-up of 8.4 months [range: 1.3-15.7 months], the median progression-free survival (PFS) was 5.4, 6.0, and 3.8 months for Arms A (n = 7), B (n = 9), and C (n = 1), respectively. Grade 3+ toxicities related to pamiparib occurred in 4 patients, with 2 adverse events resulting in treatment discontinuation. No grade 3+ toxicities were documented in the olaparib arm. CONCLUSION Pamiparib achieved pharmacologically-relevant concentrations in nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation. The majority of patients with MGMT-unmethylated GBM advanced to the phase 2 portion of the trial, and pamiparib was generally well-tolerated in these patients.
Collapse
Affiliation(s)
- W R Kennedy
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - Y W Chang
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - J Jiang
- Wayne State University, Detroit, MI
| | - J Molloy
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | | | - J Harmon
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - A Hong
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - J Wanebo
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - K Braun
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - M A Garcia
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - I J Barani
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - W Yoo
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - A Tovmasyan
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - A C Tien
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - J Li
- Wayne State University, Detroit, MI
| | - S Mehta
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - N Sanai
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| |
Collapse
|
2
|
Kennedy WR, Margaryan T, Molloy J, Knight W, Harmon J, Hong A, Wanebo J, Braun K, Garcia MA, Barani IJ, Yoo W, Tien AC, Tovmasyan A, Mehta S, Sanai N. A Combined Phase 0/2 "Trigger" Trial of Niraparib in Combination with Radiation in Patients with Newly-Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys 2023; 117:S86-S87. [PMID: 37784592 DOI: 10.1016/j.ijrobp.2023.06.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Poly ADP-ribose (PAR) polymerase (PARP) mediates DNA damage response. Niraparib is an investigational PARP1/2-selective inhibitor. We conducted a combined phase 0/2 study to evaluate niraparib pharmacokinetics (PK) and pharmacodynamics (PD) in patients with newly-diagnosed glioblastoma (GBM), graduating patients to a phase 2 study evaluating a therapeutic regimen of niraparib with concurrent conventionally-fractionated radiotherapy (RT) in O6-methylguanine methyltransferase (MGMT) unmethylated tumors exceeding a prespecified PK threshold in non-enhancing tumor. MATERIALS/METHODS Patients with presumed newly-diagnosed GBM were enrolled in a phase 0 study receiving 4 days of niraparib (300 or 200 mg QD) prior to planned resection 3-5 or 8-12 hours following the last dose. Tumor tissue (enhancing and non-enhancing regions), cerebrospinal fluid (CSF), and plasma were collected. Total and unbound niraparib concentrations were measured using validated LC-MS/MS methods. PARP inhibition was assessed by quantification of PAR induction after 10 Gy ex vivo irradiation in surgical tissue compared to non-irradiated control tissue. A PK 'trigger' determined eligibility for the therapeutic phase 2 expansion portion of the study. This was defined as unbound [niraparib] > 5-fold biochemical IC50 (i.e., 19 nM) in non-enhancing tumor. Patients with MGMT unmethylated tumors exceeding this PK threshold were eligible for expansion phase dosing of niraparib with concurrent RT followed by a maintenance phase of niraparib. Patients with MGMT methylated tumors were not eligible for the expansion phase and proceeded with temozolomide (TMZ) plus RT followed by maintenance TMZ. RT dose was 60 Gy in 30 fractions using volumetric-modulated arc therapy (VMAT). RESULTS All 29 patients enrolled in the phase 0 portion of the study met the PK threshold. In non-enhancing regions, the mean unbound concentration of niraparib was 258.2 nM. The suppression of PAR levels after ex vivo RT was observed in 79% of the patients (17/22). Sixteen patients had unmethylated tumors, and of those, 11 patients enrolled in phase 2. Five of the 6 initial patients enrolled in phase 2 experienced thrombocytopenia related to niraparib, and 3/5 cases were deemed serious and life-threatening. Consequently, starting dose in both phases was lowered to 200 mg, and no serious AEs were observed thereafter. At a median follow-up of 8.1 months [range: 6.0-12.9 months], 6-month PFS was 64% with 4 patients remaining on treatment and 5 patients ongoing survival follow-up. CONCLUSION Niraparib achieves pharmacologically-relevant concentrations in non-enhancing, newly-diagnosed GBM tissue in excess of any other studied PARP inhibitor. When delivered with concurrent RT, niraparib was well-tolerated, with low rates of grade 3+ toxicity. Initial clinical efficacy data are encouraging.
Collapse
Affiliation(s)
- W R Kennedy
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - T Margaryan
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - J Molloy
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - W Knight
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - J Harmon
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - A Hong
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - J Wanebo
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - K Braun
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - M A Garcia
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - I J Barani
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - W Yoo
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - A C Tien
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - A Tovmasyan
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - S Mehta
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| | - N Sanai
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ
| |
Collapse
|
3
|
Abstract
The 14-3-3 protein family is known to interact with various proteins involved in signaling pathways. We report here the expression pattern of the Drosophila 14-3-3 (d14-3-3epsilon) protein during embryonic development. In syncytial blastoderm when the nuclei divided rapidly, d14-3-3epsilon localized in the nuclei. During cellularization d14-3-3epsilon gradually became membrane-bound. During gastrulation, an enhanced staining in the perinuclear region was observed in various tissues. Co-labeling with dp-ERK which recognized the activated form of MAPK suggested that d14-3-3epsilon was expressed prior to MAPK activation. During neuronal differentiation, the d14-3-3epsilon protein remained at a high level in the neuronal cytoplasm.
Collapse
Affiliation(s)
- A C Tien
- Institute of Molecular Biology, Academia Sinica, Nankang, Taipei, Taiwan
| | | | | |
Collapse
|
4
|
Tien AC, Nantel M, Mourou G, Kaplan D, Bouvier M. High-dynamic-range laser-pulse-contrast measurement with a plasma-shuttered streak camera. Opt Lett 1997; 22:1559-1561. [PMID: 18188298 DOI: 10.1364/ol.22.001559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The dynamic range of a picosecond visible streak camera has been improved by the combination of a plasma shutter and multishot averaging performed with a photoconductive switch sweep circuit. We use this technique to measure the contrast of a 100-fs laser pulse over 2 ns with a dynamic range of 7 orders of magnitude.
Collapse
|
5
|
Abstract
We describe a system for achieving high-resolution range gating using optically chirped pulses. The technique converts signals from the time domain into signals in the frequency domain through a nonlinear, sum-frequency generation process. The technique is based on similar methods used in microwave radar. We draw analogies between our method and conventional and time-lens imaging processes, and present experimental results demonstrating the method.
Collapse
|
6
|
Barty CP, Korn G, Raksi F, Rose-Petruck C, Squier J, Tien AC, Wilson KR, Yakovlev VV, Yamakawa K. Regenerative pulse shaping and amplification of ultrabroadband optical pulses. Opt Lett 1996; 21:219-221. [PMID: 19865358 DOI: 10.1364/ol.21.000219] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Regenerative pulse shaping is used to alleviate gain narrowing during ultrashort-pulse amplification. Amplification bandwidths of ~ 100 nm, or nearly three times wider than the traditional gain-narrowing limit, are produced with a modified Ti:sapphire regenerative amplifier. This novel regenerative amplifier has been used to amplify pulses to the 5-mJ level with a bandwidth sufficient to support ~ 10-fs pulses.
Collapse
|
7
|
Abstract
An analysis of group-velocity dispersion in graded-index (GRIN) lenses is presented. The analysis shows that continuously adjustable negative group-velocity dispersion up to hundreds of square femtoseconds can be produced by propagating the optical beam off the axis of a GRIN lens. Compared with the well-known prism-pair and grating-pair methods for producing negative dispersion, the method described here is advantageous because it is 100-fold smaller, it has low insertion loss, and it is compatible with integrated optics.
Collapse
|